NTRK1 and synovial sarcoma: Recent preclinical evidence indicates that resistance to pazopanib treatment can occur in SS cells through various mechanisms, including activating mutations of receptor tyrosine kinase (RTK) genes found with low frequency in SS, or by an adaptive cell kinome reprogramming following prolonged exposure to the drug [17,20,21,22].